OpenWorks @ MD Anderson
Not a member yet
4211 research outputs found
Sort by
Management of Small Early-stage HER2-positive Breast Cancer: Trends and Outcomes
Get PDFhttps://openworks.mdanderson.org/sumexp23/1056/thumbnail.jp
Comparative Effects of Combustible Cigarette versus Electronic Cigarette Exposures on K-ras Mutant Lung Cancer Promotion
Get PDFhttps://openworks.mdanderson.org/sumexp23/1057/thumbnail.jp
Comparison of 18 and 20-Gauge Ultrasound-Guided Fine-Needle Aspiration in Detecting Persistent Nodal Disease after Chemoradiation
Get PDFhttps://openworks.mdanderson.org/sumexp23/1065/thumbnail.jp
Fred Flintstone Automobile, 2023
No full textArtist: Oscar G. Rangel
Materials: Recycled copper tubing and air dryers from laboratory refrigeration equipment.https://openworks.mdanderson.org/recycledart2023/1012/thumbnail.jp
From Pathology to Radiology: Bridging the Gap Using Artificial Intelligence
Get PDFJune 05, 2023
Mirabela Rusu, PhDAssistant Professor, Department of Radiology; Director, Personalized Integrative Medicine Laboratory at Stanford Universityhttps://openworks.mdanderson.org/igct_seminars/1000/thumbnail.jp
From Bench to Bedside: Surgical Margin Assessment using Machine Learning and Mass Spectrometry
Get PDFDecember 08, 2023
Parvin Mousavi, PhDProfessor, Department of Electrical and Computer Engineering at Queen’s Universityhttps://openworks.mdanderson.org/igct_seminars/1007/thumbnail.jp
Meta-Narrative Review of PD-L1 by immunotherapy on Triple-Negative Breast Cancer
Get PDFTriple-negative breast cancer (TNBC) is an aggressive form of subtype breast cancer and there are currently new treatments being discovered such as the combination of immunotherapy and chemotherapy. In immunotherapy against triple-negative breast cancer, checkpoint inhibitors like PD-1/PD-L1 treat TNBC by blocking the “off” signal that prevents T-cells from killing cancer cells. As a group, we conducted a meta-narrative review collecting results from primary sources such as clinical trials and human experimental studies to support our research question on how PD-L1 inhibitor treatments compare to other treatments in patients with TNBC. The review included articles searched from Embase, Pubmed, EMBASE, and Cochrane Library for randomized controlled trials, clinical trials, and case studies published within 5 years. The articles relate to PD-1/PD-L1 inhibitors combined with chemotherapy or PD-L1 immunotherapy for triple-negative breast cancer. The results found that PD-L1 immunotherapy treatment in combination with other forms of traditional cancer therapy, such as radiation and chemotherapy, had a slightly significant positive response. However, the treatment was overwhelmingly successful in patients who exhibited PD-L1 positive TNBC compared to patients who were PD-L1 negative. Secondly, and a major concern for immunotherapy treatment is the adverse events, potentially developing autoimmune diseases. From the articles pulled, there seemed to be no new adverse events that developed for patients outside the standard toxic effects found from radiation and chemotherapy treatment.https://openworks.mdanderson.org/rmps/1004/thumbnail.jp
A Randomized Trial of Hypnosedation Versus General Anesthesia for Women with Breast Cancer Undergoing Surgery
Get PDFReshonda Smith and Karen Cleckler-Hughes pictured.https://openworks.mdanderson.org/aprn-week-23/1003/thumbnail.jp
The MD Anderson Symptom Inventory (MDASI) survey discloses persistent moderate to high-level symptoms in cancer survivors
Get PDFcancer survivorship care; patient reported outcomeshttps://openworks.mdanderson.org/acif24/1006/thumbnail.jp